Real-world status, efficacy and prognosis analysis of first-line treatment for unresectable hepatocellular carcinoma in patients treated at multiple centres
TI was the most commonly first-line systemic therapy for uHCC patients, with better efficacy and outcomes when combined with locoregional therapy in a certain population. Baseline serum SOD and VEGF-A were found to be potential predictive biomarkers for decision-making, treatment response, and outcome in patients with uHCC in the primary care setting.
Authors
- Xu Han (ORCID: https://orcid.org/0000-0001-5410-2502)
- Mingxi Wang (ORCID: https://orcid.org/0000-0002-8093-0384)
- Qianyu Du (ORCID: https://orcid.org/0000-0002-7875-9290)
- Jing Liu (ORCID: https://orcid.org/0000-0002-5118-9259)
- Qingsheng Kan (ORCID: https://orcid.org/0000-0002-4973-2902)
- Zhengguang Zhou
- Wenting Zhang (ORCID: https://orcid.org/0000-0001-5447-2300)
- Yan Yang (ORCID: https://orcid.org/0000-0003-0887-2770)
- Xiuli Liu (ORCID: https://orcid.org/0000-0003-4936-2179)
- Yu Shao
Institutions
- Bengbu Medical College (CN)
- Anhui Medical University (CN)
- Fuyang City People's Hospital (CN)
- Fuyang Maternity and Child Health Care Hospital (CN)
- The Second Affiliated Hospital of Bengbu Medical College (CN)
- First Affiliated Hospital of Bengbu Medical College (CN)
- Fuyang Second People's Hospital (CN)
Publication Details
- Journal
- Annals of Medicine
- Published
- 2024-08-21
- DOI
- https://doi.org/10.1080/07853890.2024.2393291
- Citations
- 1
- Primary Topic
- Hepatocellular Carcinoma Treatment and Prognosis
- Type
- article
- Field-Weighted Citation Impact
- 0.37